176 related articles for article (PubMed ID: 24048802)
1. Tumor volume and patient weight as predictors of outcome in children with intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group.
Rodeberg DA; Stoner JA; Garcia-Henriquez N; Randall RL; Spunt SL; Arndt CA; Kao S; Paidas CN; Million L; Hawkins DS
Cancer; 2011 Jun; 117(11):2541-50. PubMed ID: 24048802
[TBL] [Abstract][Full Text] [Related]
2. [Clinical and prognostic analysis of single-center multidisciplinary treatment for rhabdomyosarcoma in children].
Xu N; Duan C; Jin M; Zhang DW; Su Y; Yu T; He LJ; Fu LB; Zeng Q; Wang HM; Zhang WP; Ni X; Ma XL
Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):767-773. PubMed ID: 31594063
[No Abstract] [Full Text] [Related]
3. Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group.
Hibbitts E; Chi YY; Hawkins DS; Barr FG; Bradley JA; Dasgupta R; Meyer WH; Rodeberg DA; Rudzinski ER; Spunt SL; Skapek SX; Wolden SL; Arndt CAS
Cancer Med; 2019 Oct; 8(14):6437-6448. PubMed ID: 31456361
[TBL] [Abstract][Full Text] [Related]
4. Increased local failure for patients with intermediate-risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group.
Casey DL; Chi YY; Donaldson SS; Hawkins DS; Tian J; Arndt CA; Rodeberg DA; Routh JC; Lautz TB; Gupta AA; Yock TI; Wolden SL
Cancer; 2019 Sep; 125(18):3242-3248. PubMed ID: 31174239
[TBL] [Abstract][Full Text] [Related]
5. Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.
Rudzinski ER; Anderson JR; Chi YY; Gastier-Foster JM; Astbury C; Barr FG; Skapek SX; Hawkins DS; Weigel BJ; Pappo A; Meyer WH; Arnold MA; Teot LA; Parham DM
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28521080
[TBL] [Abstract][Full Text] [Related]
6. Adolescents and young adults with rhabdomyosarcoma: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Harrison DJ; Qumseya A; Xue W; Arnold M; Lautz TB; Hiniker SM; Thomas SM; Venkatramani R; Weiss AR; Mascarenhas L
Pediatr Blood Cancer; 2024 Apr; 71(4):e30847. PubMed ID: 38282125
[TBL] [Abstract][Full Text] [Related]
7. Survival outcomes of patients with localized FOXO1 fusion-positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Heske CM; Chi YY; Venkatramani R; Li M; Arnold MA; Dasgupta R; Hiniker SM; Hawkins DS; Mascarenhas L
Cancer; 2021 Mar; 127(6):946-956. PubMed ID: 33216382
[TBL] [Abstract][Full Text] [Related]
8. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group.
Meza JL; Anderson J; Pappo AS; Meyer WH;
J Clin Oncol; 2006 Aug; 24(24):3844-51. PubMed ID: 16921036
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children's Oncology Group.
Rodeberg DA; Garcia-Henriquez N; Lyden ER; Davicioni E; Parham DM; Skapek SX; Hayes-Jordan AA; Donaldson SS; Brown KL; Triche TJ; Meyer WH; Hawkins DS
J Clin Oncol; 2011 Apr; 29(10):1304-11. PubMed ID: 21357792
[TBL] [Abstract][Full Text] [Related]
10. Results of RS-99 protocol for childhood solid tumors.
Cai JY; Tang JY; Pan C; Xu M; Xue HL; Zhou M; Dong L; Ye QD; Jiang H; Shen SH; Chen J
World J Pediatr; 2010 Feb; 6(1):43-9. PubMed ID: 20143210
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of tumor response at the end of therapy in group III rhabdomyosarcoma: a report from the children's oncology group.
Rodeberg DA; Stoner JA; Hayes-Jordan A; Kao SC; Wolden SL; Qualman SJ; Meyer WH; Hawkins DS
J Clin Oncol; 2009 Aug; 27(22):3705-11. PubMed ID: 19470937
[TBL] [Abstract][Full Text] [Related]
12. Tumor-cell DNA content predicts outcome in children and adolescents with clinical group III embryonal rhabdomyosarcoma. The Intergroup Rhabdomyosarcoma Study Committee of the Children's Cancer Group and the Pediatric Oncology Group.
Pappo AS; Crist WM; Kuttesch J; Rowe S; Ashmun RA; Maurer HM; Newton WA; Asmar L; Luo X; Shapiro DN
J Clin Oncol; 1993 Oct; 11(10):1901-5. PubMed ID: 8410116
[TBL] [Abstract][Full Text] [Related]
13. PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report.
Skapek SX; Anderson J; Barr FG; Bridge JA; Gastier-Foster JM; Parham DM; Rudzinski ER; Triche T; Hawkins DS
Pediatr Blood Cancer; 2013 Sep; 60(9):1411-7. PubMed ID: 23526739
[TBL] [Abstract][Full Text] [Related]
14. Patterns of failure and toxicity profile following proton beam therapy for pediatric bladder and prostate rhabdomyosarcoma.
Buszek SM; Ludmir EB; Grosshans DR; McAleer MF; McGovern SL; Harrison DJ; Okcu MF; Chintagumpala MM; Mahajan A; Paulino AC
Pediatr Blood Cancer; 2019 Nov; 66(11):e27952. PubMed ID: 31397065
[TBL] [Abstract][Full Text] [Related]
15. Pediatric rhabdomyosarcoma in Morocco.
Hessissen L; Kanouni L; Kili A; Nachef MN; El Khorassani M; Benjaafar N; Khattab M; El Gueddari Bel K
Pediatr Blood Cancer; 2010 Jan; 54(1):25-8. PubMed ID: 19746454
[TBL] [Abstract][Full Text] [Related]
16. Management and outcomes of chest wall rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee.
Lautz TB; Xue W; Luo LY; Fair D; Qumseya A; Gao Z; Dasgupta R; Rodeberg D; Venkatramani R
Pediatr Blood Cancer; 2023 Jul; 70(7):e30357. PubMed ID: 37070563
[TBL] [Abstract][Full Text] [Related]
17. Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low-Risk Clinical Features: A Report From the Children's Oncology Group.
Arnold MA; Anderson JR; Gastier-Foster JM; Barr FG; Skapek SX; Hawkins DS; Raney RB; Parham DM; Teot LA; Rudzinski ER; Walterhouse DO
Pediatr Blood Cancer; 2016 Apr; 63(4):634-9. PubMed ID: 26756883
[TBL] [Abstract][Full Text] [Related]
18. Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Hawkins DS; Chi YY; Anderson JR; Tian J; Arndt CAS; Bomgaars L; Donaldson SS; Hayes-Jordan A; Mascarenhas L; McCarville MB; McCune JS; McCowage G; Million L; Morris CD; Parham DM; Rodeberg DA; Rudzinski ER; Shnorhavorian M; Spunt SL; Skapek SX; Teot LA; Wolden S; Yock TI; Meyer WH
J Clin Oncol; 2018 Sep; 36(27):2770-2777. PubMed ID: 30091945
[TBL] [Abstract][Full Text] [Related]
19. The World Health Organization Classification of Skeletal Muscle Tumors in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Rudzinski ER; Anderson JR; Hawkins DS; Skapek SX; Parham DM; Teot LA
Arch Pathol Lab Med; 2015 Oct; 139(10):1281-7. PubMed ID: 25989287
[TBL] [Abstract][Full Text] [Related]
20. Treatment and outcome of patients with localized intrathoracic and chest wall rhabdomyosarcoma: a report of the Cooperative Weichteilsarkom Studiengruppe (CWS).
Fuchs J; Urla C; Sparber-Sauer M; Schuck A; Leuschner I; Klingebiel T; Blumenstock G; Seitz G; Koscielniak E
J Cancer Res Clin Oncol; 2018 May; 144(5):925-934. PubMed ID: 29464349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
